111 related articles for article (PubMed ID: 9364537)
1. Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers.
Radford J
J Clin Oncol; 2024 Jun; 42(16):1868-1870. PubMed ID: 38478798
[No Abstract] [Full Text] [Related]
2. Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study.
Subramanian S; Prasanna R; Biswas G; Das Majumdar SK; Joshi N; Bunger D; Khan MA; Ahmad I
Breast Cancer (Dove Med Press); 2020; 12():77-85. PubMed ID: 32547188
[TBL] [Abstract][Full Text] [Related]
3. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.
Brennen WN; Rosen DM; Chaux A; Netto GJ; Isaacs JT; Denmeade SR
Prostate; 2014 Sep; 74(13):1308-19. PubMed ID: 25053236
[TBL] [Abstract][Full Text] [Related]
5. Antitumour antibiotic containing regimens for metastatic breast cancer.
Lord S; Ghersi D; Gattellari M; Wortley S; Wilcken N; Simes J
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD003367. PubMed ID: 15495049
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Lamb HM; Wiseman LR
Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
[TBL] [Abstract][Full Text] [Related]
7. Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold.
Foy R; So J; Rous E; Scarffe JH
BMJ; 1999 Feb; 318(7181):456-9. PubMed ID: 9974468
[No Abstract] [Full Text] [Related]
8. Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Diéras V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):31-3. PubMed ID: 9364539
[TBL] [Abstract][Full Text] [Related]
9. The current status of docetaxel for metastatic breast cancer.
Esteva FJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Aapro M
Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
[TBL] [Abstract][Full Text] [Related]
14. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
